Susquehanna International Group
HRTX icon

Susquehanna International Group’s Heron Therapeutics HRTX Stock Holding History

Susquehanna International Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9K Buy
+13,600
New +$15.8K ﹤0.01% 12931
2025
Q4 		– Sell
-58,300
Closed -$73.5K – 12869
2025
Q3 		$73.5K Buy
58,300
+31,200
+115% +$49.5K ﹤0.01% 11724
2025
Q2 		$56.1K Buy
+27,100
New +$55.3K ﹤0.01% 12078
2025
Q1 		– Sell
-11,900
Closed -$18.2K – 12881
2024
Q4 		$18.2K Sell
11,900
-39,600
-77% -$64.2K ﹤0.01% 11931
2024
Q3 		$102K Sell
51,500
-68,000
-57% -$162K ﹤0.01% 11044
2024
Q2 		$418K Buy
119,500
+52,900
+79% +$163K ﹤0.01% 8708
2024
Q1 		$184K Buy
66,600
+28,400
+74% +$71.4K ﹤0.01% 10685
2023
Q4 		$64.9K Buy
+38,200
New +$42.1K ﹤0.01% 11594
2023
Q3 		– Sell
-33,700
Closed -$39.1K – 12397
2023
Q2 		$39.1K Buy
33,700
+20,500
+155% +$36.6K ﹤0.01% 11430
2023
Q1 		$19.9K Sell
13,200
-25,500
-66% -$63.9K ﹤0.01% 12053
2022
Q4 		$96.8K Buy
38,700
+3,600
+10% +$11.6K ﹤0.01% 10992
2022
Q3 		$148K Buy
35,100
+17,900
+104% +$70K ﹤0.01% 11253
2022
Q2 		$48K Sell
17,200
-73,600
-81% -$296K ﹤0.01% 11992
2022
Q1 		$519K Buy
+90,800
New +$664K ﹤0.01% 8878
2021
Q3 		– Sell
-24,300
Closed -$377K – 13080
2021
Q2 		$377K Sell
24,300
-21,400
-47% -$340K ﹤0.01% 10272
2021
Q1 		$741K Buy
+45,700
New +$815K ﹤0.01% 8506
2020
Q3 		– Sell
-62,200
Closed -$915K – 10780
2020
Q2 		$915K Sell
62,200
-140,900
-69% -$2.31M ﹤0.01% 6124
2020
Q1 		$2.38M Buy
203,100
+147,800
+267% +$2.78M ﹤0.01% 3666
2019
Q4 		$1.3M Sell
55,300
-37,900
-41% -$839K ﹤0.01% 5037
2019
Q3 		$1.72M Buy
93,200
+22,300
+31% +$410K ﹤0.01% 4521
2019
Q2 		$1.32M Sell
70,900
-112,100
-61% -$2.24M ﹤0.01% 5066
2019
Q1 		$4.47M Buy
183,000
+137,300
+300% +$3.59M ﹤0.01% 2587
2018
Q4 		$1.19M Buy
45,700
+8,100
+22% +$223K ﹤0.01% 4363
2018
Q3 		$1.19M Sell
37,600
-60,300
-62% -$2.25M ﹤0.01% 4892
2018
Q2 		$3.8M Sell
97,900
-91,800
-48% -$2.92M ﹤0.01% 3061
2018
Q1 		$5.24M Buy
189,700
+117,700
+163% +$2.67M ﹤0.01% 2491
2017
Q4 		$1.3M Sell
72,000
-14,400
-17% -$235K ﹤0.01% 4709
2017
Q3 		$1.4M Buy
86,400
+14,900
+21% +$234K ﹤0.01% 4614
2017
Q2 		$990K Sell
71,500
-21,700
-23% -$314K ﹤0.01% 5284
2017
Q1 		$1.4M Sell
93,200
-473,700
-84% -$6.56M ﹤0.01% 4425
2016
Q4 		$7.43M Buy
566,900
+178,300
+46% +$2.8M ﹤0.01% 1866
2016
Q3 		$6.7M Buy
388,600
+220,500
+131% +$4.09M ﹤0.01% 1905
2016
Q2 		$3.03M Buy
168,100
+51,200
+44% +$1,000K ﹤0.01% 2912
2016
Q1 		$2.22M Buy
116,900
+75,700
+184% +$1.49M ﹤0.01% 3583
2015
Q4 		$1.1M Sell
41,200
-574,900
-93% -$15.4M ﹤0.01% 5222
2015
Q3 		$15M Buy
616,100
+555,900
+923% +$18.5M 0.01% 1450
2015
Q2 		$1.88M Buy
60,200
+30,900
+105% +$581K ﹤0.01% 4861
2015
Q1 		$426K Buy
+29,300
New +$330K ﹤0.01% 7383

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Susquehanna International Group's HRTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Heron Therapeutics (HRTX) stake by 15% in Q1 2026, selling an estimated $60.2K and leaving 288,253 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #11431.

Susquehanna International Group first reported a position in HRTX in Q2 2014 and has held it in 46 quarters since. The position peaked at $27.8M in Q2 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Susquehanna International Group held 288,253 shares of Heron Therapeutics worth $231K as of Q1 2026.
  • Susquehanna International Group sold 51,993 Heron Therapeutics shares in Q1 2026, an estimated $60.2K.
  • Heron Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11431 holding.
  • Susquehanna International Group first reported a position in Heron Therapeutics in Q2 2014 and has held it in 46 quarters since.
  • Susquehanna International Group's Heron Therapeutics position peaked at $27.8M in Q2 2015.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.